Drug Profile
Galsulfase - BioMarin Pharmaceutical
Alternative Names: arylsulfatase B; Aryplase™; BM 102; Naglazyme; Recombinant human arylsulfatase B; recombinant human N-acetylgalactosamine-4-sulfatase; rhASBLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator BioMarin Pharmaceutical
- Developer AnGes; BioMarin Pharmaceutical; Medison Pharma
- Class Arylsulfatases; Recombinant proteins
- Mechanism of Action N acetylgalactosamine 4 sulfatase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Mucopolysaccharidosis VI
Most Recent Events
- 31 Dec 2020 BioMarin Pharmaceutical has patent protection for Galsulfase in USA and European union
- 23 Dec 2020 Masonic Cancer Center, University of Minnesota and BioMarin Pharmaceutical terminates a clinical study in Mucopolysaccharidosis VI in USA due to low patient accural (NCT02156674)
- 03 Jan 2020 AnGes MG is now called AnGes